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SUMMARY
Topical antibacterial agents are being widely used for the treatment and prevention of superficial skin infec-
tions. The most frequent problems with many of the topical agents are the rapidly development of resistant
mutant strains of microorganisms and the possibility of appearance of irritant and allergic contact dermatitis.
This article emphasizes on their spectrum of activity, ressistance patterns, contact sensitivity potential and
clinical uses.
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The beginning and the development of any infectious pro-
cess or infection disease depends on three groups of factors
- features of the microorganism, characteristics and the sta-
tus of the microorganism and the environment.
The pathogen and the virulent abilities of the microorgan-
isms depend on their possibilities to adhere, to colonize, to
invade and to reproduce in the infected organism; to secrete
toxins and enzymes; to protect itself against the natural re-
sistance and to overcome or withstand the constant pressure
of the host immunity defenses the of the microorganism.
The adherence is the process or condition of adhering to the
cells of the microorganism. The adhesion possibility of
many bacterial species is prerequisite for their colonization.
The colonization is the establishment of the pathogen at the
appropriate portal of entry /for example the urogenital tract,
the digestive tract, the respiratory tract and the conjunctiva/.
The colonization is marked with location, development and
reproduction of the infectious agent over and in the host tis-
sues. Once the so called "critical colonization" is reached
the infectious process is transformed into infectious disease
with its typical or not so typical symptoms caused by the
pathogen damage process on the different organism's, cell
or molecule levels. The prevention of the development of
the critical colonization is crucial for the progress of the in-
fectious process and in the terms of the dermatology for the
faster granulation and epitelization of the tissue and the pre-
vention of superinfection.
The application of the topical antimicrobial agents aims the
prevention of this critical colonization. In the dermatology
practice the choice of a topical agent depends on the microor-
ganism isolated, its susceptibility features and its ability to be-
come resistant as well as the possibility of sensitization of the
microorganism. Drugs as Neomycin, Bacitracin or lano-
lin-containing may increase the inflammation and are consid-
ered to cause sensitization. The topical aminoglycosides for
example gentamicin increase the risc of development of drug
resistance. On Table 1 are shown some of the most frequently
used in the clinical practice topical antibacterial agents.
The topical antibacterial drugs are being used for the treat-
ment and the prevention of wide spectrum bacterial
dermatologic infections and in other branches of our medi-
cine. These agents may substitute the use of systemic anti-
biotics in the case of mild or moderate skin bacterial infec-
tion but their long time or unreasonable application is not
harmless. For example emergence of drug resistant mutant
strains of microorganisms or development of irritant or al-
lergic contact dermatitis are frequent. That is the reason
why the debate for the usage of topical antibacterial instead
their systemic analogs is still a question of interest. The
analysis of the data in the literature reveals the need of elu-
cidation of the advantages or disadvantages of the different
topical antimicrobial agents, including the more and more
frequently used compounds like fusidic acid, mupirocin,
octenisept that show low levels of acquired resistance or
development of allergic reactions.
Mupirocin - one of the main metabolites of Pseudomonas
fluorescens that shows strong antibacterial activity against
coagulase negative and coagulase positive staphylococci
including MRSA strains. This antibacterial agent with its
wide specturum of activity against Streptococci,
Peptostreptococci, Clostridium spp., Haemophilus
influenzae, Neisseria spp., E. coli, K. pneumoniae, Proteus
spp., and Enterobacter spp., is unique among the topical
skin drugs (8,17). Mupirocin's disadvantage is its low ef-
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fectiveness in the presence of serum or exudates because
95% of the drug is protein bound. In the clinical practice it
is used for the treatment of impetigo, folliculitis,
impetiginized eczema, burns, lacerations. Intranasal
Mupirocin is effective for the elimination and prolonged
suppression of staphylococcal carriage including MRSA
strains (17). The prolonged intranasal usage have shown
decrease of the rate of recurrent skin infections in
immunocompetent patients. The drug has very low inci-
dence of skin sensitization and cross-reactivity (14). Its
widespread use is the reason for the more and more fre-
quently found resistance among MRAS strains.
Sodium fusidate is derivate of fusidic acid and is isolated
from the fungus Fusidium coccineus. Its steroid-like struc-
ture is responsible for the ability of penetration in damaged
structures even in the presence of different kind of
exudates. Other feature of the drug is its low or missing
cross resistance and sensitization with other topical
antibacterials (5). Its spectrum assume Gram positive bac-
teria such as S. aureus, S. åpidermidis, Nocardia asteroids,
Clostridium spp. and MRSA (15). There are dada that an-
nounce activity against Neisseria spp., Bacteroides fragilis,
Mycobacterium tuberculosis and Mycobacterium leprae.
The drug with its 2% cream variant may be used as mono
therapeutic agent in case of staphylococcal cutaneous in-
fection or in combination with topical steroids in the atopic
dermatitis. It must be stressed that the frequency of contact
sensitivity to the fusidic acid is low. Low is the bacterial re-
sistance toward the drug nevertheless yet there are fusidic
acid resistant S. aureus strains (12).
Neomycin is an aminogycoside antibiotic isolated from
Streptomyces fradiae. The drug shows effectiveness
against Gram positive and Gram negative microorganisms
including S. aureus, S. pyogenes, E. coli, H. influenzae,
Klebsiella and Proteus. In combination with Polymyxin-B
or Bacitracin the antibacterial is used for the prevention of
infections in abrasions, burns or superficial skin infections
(11). The incidence of contact sensitization to neomycin
depends on the frequency of its usage. The allergic contact
dermatitis develops between 0,9 - 11% (14) and patients
with hypostatic eczema, leg ulcerations or post-operative
wounds are prone to neomycin sensitivity. It is not rare the
cross sensitivity and resistance with other aminoglycosides.
For this reason it is better to use neomycin in combination
with Bacitracin or Polymyxin-B (3).
Framycetin is another aminoglycoside, mixture of
Neomycin-B, Neomycin-C and neamine. It has wide activ-
ity spectrum - both Gram negative and Gram positive mi-
croorganisms including S. aureus, S. pyogenes, E. coli, H.
influenzae, Klebsiella spp. and Proteus spp. (1). The drug is
considered to be the third most frequent sensitizer after
Nitrofurazone and Neomycin (4). From the other side the
cross sensitivity among Framycetin and Neomycin is quite
common.
The aminoglycoside Gentamicin is derivate of
Micromonospora purpurea. It is effective against S. aureus
and Gram negative microorganisms like E. coli, Proteus
spp. and P. aeruginosa (8). The drug shows relatively low
sensitizing abilities in comparison with Neomycin but
strong cross reactivity between the two (4). Its frequent use
as topical agent have let to the development of high levels
of easy resistance (19).
Bacitracin, produced by Bacillus subtilis and Bacillus
licheniformis, is one of the most frequently applied antibi-
otics in the microbiology practice. Its spectrum S. aureus, S.
pneumoniae, Neisseria spp., H. influenzae, and other Gram
positive microorganisms (9). It demonstrates minimal ac-
tivity against Gram negative organisms and is not active
against P. aeruginosa, Nocardia, Enterobacteriaceae and
Cryptococcus. Its sensitizing ability depends on many fac-
tors and varies widely (14,20).
Polymyxin-B is cyclic decapeptide isolated form Bacillus
polymyxa. It is effective against Gram negative microor-
ganisms like P. mirabilis, P. aeruginosa, S. marcescens,
predominantly used in combination with other topical
agents (8). Its contact sensitivity is lesser as compared with
Neomycin and Bacitracin (14).
Octenisept is a colorless water-soluble disinfectant with
wide spectrum of activity that stimulates the physiological
process of recovery of damaged skin structures. It could be
used for a long time, nevertheless resistance occurs rarely.
In the composition of Octenisept does not enter toxic sub-
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Table 1. Some of the most frequently used in the
dermatological practice topical antibacterial agents.
stances and the visual control of the damaged skin wound is
easy. This antibacterial product affects Gram positive
staphylococci, including MRSA, streptococci, enterococci,
Neisseria spp., E. coli, P. aeruginosa, Proteus spp.,
Klebsiella spp., Mycobacterium spp., fungi and vira. Its ac-
tivity in the presence of blood, blood products or proteins
remains unchanged (16).
Erythromycin is a macrolide agent isolated from
Streptomyces erythraeus. It is used in the therapy of infec-
tions caused by Gram positive cocci, Corynebacterium
diphtheriae, H. influenzae, L. pneumophila, Chlamydia
spp. (8). Its topical use is restricted to the treatment of acne
vulgaris, erythrasma and pitted keratolysis (6).
Erythromycin shows weak sensitizer activity. Because of
its wide usage in the practice the resistance increases rap-
idly. Propionibacterium acnes may become resistant in pa-
tients with acne. The prevalence of coagulase negative
staphylococci ranges between 87-99,8%.
Clindamycin is a derivate of Lincomycin, isolated by
Streptomyces spp. Its activity spectrum includes most of the
aerobic Gram positive cocci, the anaerobic Gram negative
and positive bacteria even Propionibacterium acnes. Al-
though it has been used effectively in erythrasma,
folliculitis, rosacea and Fox-Fordyce disease nowadays its
use is restricted to acne vulgaris (2). Rare are the cases with
contact allergies caused by its usage (18). A few data exist
of Clindamycin resistant P. acnes.
Silver sulfadiazine is a synthetic product which acts
through slow release of silver into the damaged tissues. Its
spectrum includes Gram positive and Gram negative mi-
croorganisms, MRSA, P. aeruginosa and anaerobes (8).
Available as 1% cream it is used for burnt skin and its
emollient effect keeps eschar soft. Studies show that Silver
sulfadiazine is very appropriate for superficial cutaneous
infections. Few are the contact sensitivity reactions and
only in burn patients (7).
Metronidazole is a synthetic nitroimidazole. Applied as
0,75% or 1% cream or gel it is effective against the
anaerobes including Bacteroides fragilis, Fusobacterium,
Clostridium, Peptococcus, Trichomonas vaginalis. The
drug may be used in case of rosacea, acne vulgaris or skin
ulcerations (8). Few are the registered cases with developed
contact sensitivity.
Povidone-iodine is may be the most commonly used iodofor
in the practice - a combination of surfactant and iodine. It is
active against Gram positive and Gram negative bacteria. Its
5% and 10% concentration variants are used as anticeptics
before different types of operations and for skin wounds
(10). Contact dermatitis toward the drug is rare however
prolonged exposure may lead to irritant contact dermatitis,
tissue necrosis or systemic adverse effects. Is spite of the
good in vitro effectiveness against S. aureus, the in vivo test
are negative so the drug could not be used for this purpose.
Topical antimicrobial agents like tetracyclines,
chloramphenicol, gentian violet are discard form the prac-
tice. Other substances such as cetrimid, chlorhexidine or
triclosan are mostly used for anticeptic treatment of the skin
surfaces.
The data form the literature show us that the topical
antibacterials are used alone or in combination with other
products in the cases of mild to moderate infections affect-
ing small or superficial areas of the skin (13). They provide
prevention and good control of restricted cutaneous infec-
tions. While selecting a topical antibacterial agent for a par-
ticular infection it is important to take in mind the spectrum
of activity, the resistance of the isolated bacteria and the
contact sensitivity potential. The aim is to obtain maximum
efficacy and minimum adverse effects.
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